Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/16/2025

Contraception and Medication Interactions

Introduction to Contraception and Medication Interactions

  • The Centers for Disease Control and Prevention (CDC) classifies certain medications, such as rifampin, as Category 3 (risks generally outweigh benefits) for combined hormonal contraceptives, indicating a significant reduction in contraceptive effectiveness 1
  • The CDC also classifies rifampin as Category 3 for progestin-only pills and implants, suggesting that alternative contraceptive methods should be considered 1
  • For depot medroxyprogesterone acetate (DMPA) injections, rifampin is classified as Category 1 (no restriction), as its effectiveness is not decreased by rifampin use 1

Alternative Contraceptive Methods

  • The CDC recommends considering alternative contraceptive methods, such as DMPA injections, which are not affected by rifampin 1
  • Barrier methods, such as condoms, used consistently can also be an effective alternative 1
  • Intrauterine devices (IUDs) may also be considered as an alternative contraceptive method 1

Contraceptive Effectiveness and Medication Interactions

  • Certain medications, such as rifampin, can significantly reduce the effectiveness of combined hormonal contraceptives by inducing hepatic metabolism 1
  • Other medications, including certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone, topiramate, and oxcarbazepine) and ritonavir-boosted protease inhibitors, can also reduce contraceptive effectiveness by decreasing contraceptive hormone levels 1
  • Non-nucleoside reverse transcriptase inhibitors (NNRTIs), such as efavirenz and nevirapine, can reduce hormonal levels, while etravirine and rilpivirine do not appear to cause the same reduction 2
  • Nucleoside reverse transcriptase inhibitors (NRTIs), integrase inhibitors (raltegravir, dolutegravir), entry inhibitors (maraviroc), and fusion inhibitors (enfuvirtide) do not have significant interactions with oral contraceptive pills (OCPs) 2

Managing Contraceptive Interactions

  • The CDC recommends choosing OCP preparations containing at least 30-35 μg of ethinyl estradiol when alternative methods are not available, and advising consistent use of condoms as a backup method 1
  • For women on ritonavir-boosted protease inhibitors or efavirenz/nevirapine, the Pediatrics journal recommends considering alternative or additional contraceptive methods, and using preparations with ≥30 μg ethinyl estradiol if combined hormonal contraceptives are used 2
  • Consistent condom use is recommended to prevent HIV transmission and compensate for possible reduced contraceptive effectiveness 1
  • The following table summarizes the effect of contraceptive methods on lamotrigine levels:
Contraceptive Method Effect on Lamotrigine Levels CDC Classification
Progestin-only contraceptives No significant effect Category 1
Combined hormonal contraceptives Significant reduction (40-60%) Category 3
  • The CDC recommends choosing progestin-only methods as first-line options and avoiding combined hormonal contraceptives containing ethinyl estradiol for women taking lamotrigine 1, 3
  • Clinicians should monitor for breakthrough seizures during active hormone weeks and watch for signs of lamotrigine toxicity during hormone-free weeks, and consider adjusting lamotrigine dosing throughout the cycle 1, 3

Clinical Considerations

  • Failure to take a complete medication history when prescribing OCPs can lead to unintended contraceptive interactions, and assuming all antibiotics reduce OCP effectiveness can result in inadequate contraception 1
  • Not providing backup contraception when starting enzyme-inducing medications can increase the risk of contraceptive failure, and overlooking bidirectional interactions can lead to reduced effectiveness of other medications 1
  • Clinicians should monitor for signs of contraceptive failure (breakthrough bleeding) when adding potentially interacting medications, and identifying the interacting medication and determining interaction severity are crucial steps in managing contraceptive interactions 1
  • The CDC recommends measuring lamotrigine serum concentrations before starting hormonal contraception, 2-3 weeks after starting, and after any change in regimen, and adjusting the lamotrigine dose based on serum concentrations and clinical response 1